Literature DB >> 22879486

Comment on "Impaired respiratory and body temperature control upon acute serotonergic neuron inhibition".

Stefan Löffler1, Jochen Körber, Udo Nubbemeyer, Karin Fehsel.   

Abstract

Ray et al. (Reports, 29 July 2011, p. 637) assume that clozapine-N4-oxide (CNO) represents a "biologically inert synthetic ligand" that selectively activates the M4 muscarinic receptor-based DREADD (designer receptor exclusively activated by a designer drug). In contrast, due to the redox cycling of CNO with clozapine and to their cell membrane permeability, CNO is biologically active and its conversion products are capable of undermining DREADD effects.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22879486     DOI： 10.1126/science.1221810

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  10 in total

1.  Inhibition of mediodorsal thalamus disrupts thalamofrontal connectivity and cognition.

Authors:  Sebastien Parnaudeau; Pia-Kelsey O'Neill; Scott S Bolkan; Ryan D Ward; Atheir I Abbas; Bryan L Roth; Peter D Balsam; Joshua A Gordon; Christoph Kellendonk
Journal:  Neuron       Date:  2013-03-20       Impact factor: 17.173

Review 2.  Optogenetic approaches for dissecting neuromodulation and GPCR signaling in neural circuits.

Authors:  Skylar M Spangler; Michael R Bruchas
Journal:  Curr Opin Pharmacol       Date:  2016-11-19       Impact factor: 5.547

3.  Gi-DREADD Expression in Peripheral Nerves Produces Ligand-Dependent Analgesia, as well as Ligand-Independent Functional Changes in Sensory Neurons.

Authors:  Jami L Saloman; Nicole N Scheff; Lindsey M Snyder; Sarah E Ross; Brian M Davis; Michael S Gold
Journal:  J Neurosci       Date:  2016-10-19       Impact factor: 6.167

4.  The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.

Authors:  Xin Chen; Hyunah Choo; Xi-Ping Huang; Xiaobao Yang; Orrin Stone; Bryan L Roth; Jian Jin
Journal:  ACS Chem Neurosci       Date:  2015-01-27       Impact factor: 4.418

Review 5.  The Use of DREADDs to Deconstruct Behavior.

Authors:  Paul D Whissell; Sarasa Tohyama; Loren J Martin
Journal:  Front Genet       Date:  2016-05-17       Impact factor: 4.599

6.  Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice.

Authors:  Martin Jendryka; Monika Palchaudhuri; Daniel Ursu; Bastiaan van der Veen; Birgit Liss; Dennis Kätzel; Wiebke Nissen; Anton Pekcec
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

7.  Chemogenetic Silencing of Differentiating Cortical Neurons Impairs Dendritic and Axonal Growth.

Authors:  Ina Gasterstädt; Max Schröder; Lukas Cronin; Julian Kusch; Lisa-Marie Rennau; Brix Mücher; Stefan Herlitze; Alexander Jack; Petra Wahle
Journal:  Front Cell Neurosci       Date:  2022-07-15       Impact factor: 6.147

Review 8.  Control of cutaneous blood flow by central nervous system.

Authors:  Youichirou Ootsuka; Mutsumi Tanaka
Journal:  Temperature (Austin)       Date:  2015-07-28

9.  Activation of the Medial Prefrontal Cortex Reverses Cognitive and Respiratory Symptoms in a Mouse Model of Rett Syndrome.

Authors:  C James Howell; Michael P Sceniak; Min Lang; Wenceslas Krakowiecki; Fatimah E Abouelsoud; Saloni U Lad; Heping Yu; David M Katz
Journal:  eNeuro       Date:  2018-01-10

10.  Gram scale preparation of clozapine N-oxide (CNO), a synthetic small molecule actuator for muscarinic acetylcholine DREADDs.

Authors:  Phillip L van der Peet; Christian Gunawan; Alaa Abdul-Ridha; Sherie Ma; Daniel J Scott; Andrew L Gundlach; Ross A D Bathgate; Jonathan M White; Spencer J Williams
Journal:  MethodsX       Date:  2018-03-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.